Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Estradiol valerate is a synthetic estrogen and prodrug of estradiol, the primary female sex hormone. It is an esterified form of estradiol that, once administered (typically by intramuscular injection), is rapidly hydrolyzed in the body to release active estradiol. Estradiol acts as an agonist at estrogen receptor (ERα and ERβ) in various tissues, mediating typical estrogenic effects such as regulation of reproductive function and secondary sexual characteristics. Estradiol valerate is used for hormone replacement therapy to treat moderate-to-severe vasomotor symptoms (hot flashes), vulvar and vaginal atrophy due to menopause, hypoestrogenism from hypogonadism or ovarian failure, palliative treatment of advanced androgen-dependent prostate cancer, and in combination with other agents for contraception or management of heavy menstrual bleeding[1][2][3][4][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on estradiol valerate.